Skip to main content
Premium Trial:

Request an Annual Quote

Catalysis Foundation for Health Taps BioFortis Labmatrix for Tuberculosis Biomarker Study

Premium

This week, BioFortis said that the Catalysis Foundation for Health has selected its Labmatrix database software system to manage an international tuberculosis diagnostic biomarker study funded by the Bill and Melinda Gates Foundation.

Specifically, CFH researchers and their collaborators will use the platform to collect and manage patient specimen data and clinical information, track shipment status, analyze data from thousands of patient biospecimens, and view real-time study results from pre-built or ad hoc data queries.

Furthermore, BioFortis said Labmatrix will improve data quality, consistency, and privacy using its secure project messaging capabilities, standardized electronic case report forms, prescription drug forms, biospecimen and assay result forms, and other workflow-driven information capture mechanisms.

Richard Thayer, CFH's chief executive, said the tool will allow researchers participating in the study to "quickly and securely exchange pertinent information across international sites," thus "facilitating both study data management and patient sample management for this complex tuberculosis diagnostic biomarker project."

CFH is a not-for-profit organization that develops diagnostic tests for resource-poor settings.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.